After a transformative 2025 driven by positive data across its chronic cough programs, Trevi Therapeutics Inc. (TRVI) is gaining momentum and is now set to begin its first pivotal trial in IPF-related chronic cough this quarter.
Chronic cough is often the first symptom associated with idiopathic pulmonary fibrosis (IPF), a rare and progressive lung disease. Around 150,000 people in the U.S. have IPF. About 60-70% of those with IPF experience uncontrolled coughing, which can be severe, reaching up to 1,500 coughs per day. Currently, there are no approved treatments for chronic cough in IPF patients.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com